FDA Okays Perioperative Durvalumab for Bladder Cancer

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-okays-perioperative-durvalumab-regimen-muscle-invasive-2025a10007rs?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost